Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H25FN2O |
| Molecular Weight | 364.4558 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=C3C=C(F)C=C4)C5=CC=CC=C5
InChI
InChIKey=AMXGKMSRYLZAEO-YHBQERECSA-N
InChI=1S/C23H25FN2O/c1-25-22(16-5-3-2-4-6-16)10-12-23(13-11-22)21-18(9-14-27-23)19-15-17(24)7-8-20(19)26-21/h2-8,15,25-26H,9-14H2,1H3/t22-,23-
| Molecular Formula | C23H25FN2O |
| Molecular Weight | 364.4558 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lexanopadol is a potent ORL-1 agonist (opioid receptor like -1), nociceptin receptor agonists and opioid mu receptor agonists. Preliminary evidence suggests that targeting ORL-1 receptors may have synergistic effects with mu receptors hence enhancing the therapeutic profile of Lexanopadol in the treatment of pain. Lexanopadol is particularly suited for the management of moderate to severe chronic pain, including neuropathic pain. Lexanopadol hemicitrate is in phase II clinical trials for the treatment of pain. However there is no recent development reported.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:26:41 GMT 2025
by
admin
on
Mon Mar 31 22:26:41 GMT 2025
|
| Record UNII |
DZ4NDW1LZX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C170119
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
1357348-09-4
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
DZ4NDW1LZX
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
300000034332
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL3301613
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
24798598
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
9765
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY | |||
|
BC-23
Created by
admin on Mon Mar 31 22:26:41 GMT 2025 , Edited by admin on Mon Mar 31 22:26:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|